NasdaqCM:CORTPharmaceuticals
A Look At Corcept Therapeutics (CORT) Valuation After Higher 2026 Guidance And New ALS Trial Data
Earnings miss, higher guidance and new ALS data reshape the Corcept story
Corcept Therapeutics (CORT) has given investors a mixed update, pairing a first quarter net loss with higher 2026 revenue guidance and fresh two year survival data from its Phase 2 DAZALS ALS study.
The company reported a net loss of US$31.76 million for the quarter ended March 31, 2026, compared with net income of US$20.55 million a year earlier, with basic and diluted loss per share of US$0.30 from continuing...